Comparison of the effect of liposomal clarithromycin plus glucantime and glucantime in treatment of cutaneous leishmaniasis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171230038142N17

Enrollment

Registered

2020-03-27

Start date

2019-12-22

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

leishmaniasis. Leishmaniasis

Interventions

Intervention 1: Control group: Patients with leishmania are treated with glucantime and placebo for 28 days and three times daily. To prescribe this medicine, the patient is first fully instructed and

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Ages 15 to 65 years Skin lesion with a diameter greater than 5 cm Cartilage or articular or facial lesion Number of lesions over 5 in patient Leishmania's disease has been proven by the patient's Smear For Leishman Body Test.

Exclusion criteria

Exclusion criteria: Pregnant or lactating patients. History of concurrent or previous treatment for the lesion. Have heart, kidney, liver problems, drug side effects. The patient's unwillingness.

Design outcomes

Primary

Measure	Time frame
The size of the lesion. Timepoint: Before, 6 weeks, 12 weeks and 6 months after intervention. Method of measurement: Physical examination.;Frequency of waste. Timepoint: Before, 6 weeks, 12 weeks and 6 months after intervention. Method of measurement: Physical examination.;Drug side effects. Timepoint: 6 weeks, 12 weeks and 6 months after intervention. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Radmehr

Esfahan University of Medical Sciences

mehrradreza1@Yahoo.Com+98 31 3668 8597

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026